Literature DB >> 11397774

Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase.

V Sauzeau1, E Le Mellionnec, J Bertoglio, E Scalbert, P Pacaud, G Loirand.   

Abstract

The aim of this work was to investigate the coupling of human urotensin II (hU-II) to RhoA activation and regulation of RhoA-dependent functions. The use of the Rho-kinase inhibitor Y-27632 and the development of a membrane-permeant RhoA inhibitor (TAT-C3) allowed us to demonstrate that hU-II induced arterial smooth muscle contraction, actin stress fiber formation, and proliferation through the activation of the small GTPase RhoA and its downstream effector Rho-kinase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397774     DOI: 10.1161/hh1101.092034

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  58 in total

Review 1.  Protein kinase network in the regulation of phosphorylation and dephosphorylation of smooth muscle myosin light chain.

Authors:  Katusya Hirano; Dmitry N Derkach; Mayumi Hirano; Junji Nishimura; Hideo Kanaide
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

2.  Role of Rho kinase signalling in healthy and varicose human saphenous veins.

Authors:  Chrystelle Cario-Toumaniantz; Sandrine Evellin; Séverine Maury; Olivier Baron; Pierre Pacaud; Gervaise Loirand
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

Review 3.  Cardiovascular actions of human urotensin II--considerations for hypertension.

Authors:  Fraser D Russell; Peter Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

4.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

5.  Urotensin II alters vascular reactivity in animals subjected to volume overload.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa; Christopher J Wingard
Journal:  Peptides       Date:  2010-08-17       Impact factor: 3.750

Review 6.  C3 exoenzymes, novel insights into structure and action of Rho-ADP-ribosylating toxins.

Authors:  Martin Vogelsgesang; Alexander Pautsch; Klaus Aktories
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-12-05       Impact factor: 3.000

7.  Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling.

Authors:  Ana Patrícia Fontes-Sousa; Carmen Brás-Silva; Ana Luísa Pires; Daniela Monteiro-Sousa; Adelino F Leite-Moreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-14       Impact factor: 3.000

Review 8.  Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.

Authors:  Naoki Sawada; James K Liao
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

9.  Intra-ventral tegmental area microinjections of urotensin II modulate the effects of cocaine.

Authors:  L E Mueller; M A Kausch; T Markovic; D A A MacLaren; D M Dietz; J Park; S D Clark
Journal:  Behav Brain Res       Date:  2014-10-01       Impact factor: 3.332

Review 10.  The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction.

Authors:  Karl Swärd; Mitsuo Mita; David P Wilson; Jing Ti Deng; Marija Susnjar; Michael P Walsh
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.